Abstract
We welcome the insightful and constructive comments by our colleagues, Dr Thomas Johnson et al, with regard to our recent report on bleeding outcomes with various antithrombotic regimens used in the Ottawa ST-segment–elevation myocardial infarction registry.1 As highlighted in our article, patients were recruited between 2006 and 2010, during which the publication of the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI)2 study occurred, resulting in an increased use of bivalirudin by operators in our center. Moreover, as a nonrandomized study, important differences in bleeding reduction strategies, such as radial access,3 existed …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
